Zoetis Inc. $ZTS Shares Purchased by Mill Capital Management LLC

Mill Capital Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 6.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 173,822 shares of the company’s stock after purchasing an additional 11,122 shares during the quarter. Zoetis accounts for approximately 1.6% of Mill Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. Mill Capital Management LLC’s holdings in Zoetis were worth $20,547,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. J. Stern & Co. LLP increased its position in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter valued at $734,425,000. Vanguard Group Inc. boosted its position in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Nordea Investment Management AB boosted its position in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Finally, Van ECK Associates Corp increased its holdings in Zoetis by 269.0% in the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after purchasing an additional 1,740,113 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZTS shares. JPMorgan Chase & Co. cut their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barclays lowered their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. TD Cowen reduced their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Finally, Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $123.46.

Zoetis Stock Performance

NYSE:ZTS opened at $74.08 on Wednesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a 50-day moving average of $78.40 and a two-hundred day moving average of $106.94. The stock has a market cap of $31.06 billion, a P/E ratio of 12.29, a PEG ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the business earned $1.48 earnings per share. The firm’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s payout ratio is currently 35.16%.

Insiders Place Their Bets

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 11,650 shares of company stock worth $886,384 in the last three months. 0.22% of the stock is owned by insiders.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis announced a deal to acquire VitalRADS, a provider of veterinary imaging services, which could support growth in its animal-health business by expanding diagnostic capabilities. Zoetis to acquire VitalRADS, a provider of veterinary imaging services
• Neutral Sentiment: Several firms, including Rosen, Glancy Prongay Wolke & Rotter, the Gross Law Firm, Levi & Korsinsky, and others, issued reminders about the Zoetis securities class action and the upcoming deadline, increasing the amount of negative press but not adding new case details. Pomerantz law firm investor alert
• Negative Sentiment: The class action alleges Zoetis and certain executives made misleading statements about companion-animal product performance while safety concerns and competitive losses were building, which is weighing on investor sentiment. ZTS shareholder alert
• Negative Sentiment: The stock also appears to be reflecting a weaker trading tone after recent earnings disappointment, with Zoetis having previously missed analyst estimates on EPS and revenue, adding to concerns about near-term fundamentals. Zoetis stock dips while market gains: key facts

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.